Regeneron Pharmaceuticals
REGN
1,159 hedge funds and large institutions have $66.7B invested in Regeneron Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 170 funds opening new positions, 339 increasing their positions, 462 reducing their positions, and 71 closing their positions.
139% more first-time investments, than exits
New positions opened: 170 | Existing positions closed: 71
7% more funds holding
Funds holding: 1,080 → 1,159 (+79)
1.06% more ownership
Funds ownership: 86.95% → 88.01% (+1.1%)
4% more capital invested
Capital invested by funds: $64B → $66.7B (+$2.74B)
12% less funds holding in top 10
Funds holding in top 10: 34 → 30 (-4)
19% less call options, than puts
Call options by funds: $1.27B | Put options by funds: $1.57B
27% less repeat investments, than reductions
Existing positions increased: 339 | Existing positions reduced: 462
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
+$1.09B |
| 2 |
JP Morgan Chase
New York
|
+$298M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$258M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$212M |
| 5 |
Goldman Sachs
New York
|
+$96.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$280M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$239M |
| 3 |
BlackRock
New York
|
-$236M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$189M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$187M |
REGN Hedge Fund Activity: Q4 2022 in Review
1,159 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2022, worth a combined $66.7B — up 4.3% from $64B a quarter earlier.
Buyers outnumbered sellers: 170 funds opened new REGN positions and 71 closed out — a net gain of 99 holders — while 339 added to existing stakes and 462 trimmed.
The largest buyer was Westwood Holdings Group, adding an estimated $1.09B. The largest seller was Loomis, Sayles & Company, cutting an estimated $280M.
- 1,159 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2022, up from 1,080 in Q3 2022.
- Funds reported $66.7B of Regeneron Pharmaceuticals stock for Q4 2022, up 4.3% quarter-over-quarter.
- 170 funds opened new Regeneron Pharmaceuticals positions in Q4 2022 and 71 closed out, a net change of +99 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2022 was Westwood Holdings Group, an estimated $1.09B added.
- The largest Regeneron Pharmaceuticals seller in Q4 2022 was Loomis, Sayles & Company, an estimated $280M sold.
Based on aggregated 13F filings for Q4 2022.